Prosecution Insights
Prosecution Insights
22 pending office actions • 12 clients • 21 examiners • 14 art units • 0 of 22 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (27%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 3 (14%) |
| Multi-statute (no §101) | 12 (55%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 2 | 66.7% | +22.8% |
| RAHMAN, MASUDUR | 1 | 71.3% | +32.3% |
| FAUST, AMBER KATHLEEN | 1 | 60.3% | +53.6% |
| JARRELL, NOBLE E | 1 | 80.9% | +9.6% |
| BARSKY, JARED | 1 | 50.3% | +23.1% |
| ABBOTT, KODYE LEE | 1 | 57.7% | +64.7% |
| POPA, ILEANA | 1 | 21.5% | +14.6% |
| SCHUBERG, LAURA J | 1 | 23.7% | +37.2% |
| STEELE, AMBER D | 1 | 59.0% | +9.7% |
| GONZALES, JOSEPHINE MARIA | 1 | 27.9% | +40.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009320 | CHIMERIC ANTIGEN RECEPTOR CELL | VIVLEMORE, TRACY ANN | 86d overdue |
| 18003124 | ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY | SCHUBERG, LAURA J | 25d overdue |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 69d |
| 17909427 | Replication Competent Virus Assay | WANG, RUIXUE | 69d |
| 17503088 | Gene Therapy | CORDAS, EMILY ANN | 69d |
| 18718051 | Purification Method of Viral Vectors | RAHMAN, MASUDUR | — |
| 18575804 | Method of Administering Anti-HPA-1a Monoclonal Antibody | STOICA, ELLY GERALD | — |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | FAUST, AMBER KATHLEEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | BARSKY, JARED | 89d overdue |
| 18003124 | ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY | SCHUBERG, LAURA J | 25d overdue |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 69d |
| 18718051 | Purification Method of Viral Vectors | RAHMAN, MASUDUR | — |
| 18575805 | Administration of Anti-HPA-1a Antibodies | STOICA, ELLY GERALD | — |
| 18575804 | Method of Administering Anti-HPA-1a Monoclonal Antibody | STOICA, ELLY GERALD | — |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | FAUST, AMBER KATHLEEN | — |
| 18041080 | CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS | ABBOTT, KODYE LEE | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1634 | 2 |
| 1632 | 2 |
| 1699 | 1 |
| 1628 | 1 |
| 1633 | 1 |
| 1658 | 1 |
| 1638 | 1 |
| 1672 | 1 |
| 1671 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18718051 | Purification Method of Viral Vectors | Oxford Biomedica (Uk) Limited | RAHMAN, MASUDUR | §102§103 | Non-Final OA | — | Pending | Jun 09, 2024 | |
| 18575805 | Administration of Anti-HPA-1a Antibodies | Rallybio Ipa, LLC | STOICA, ELLY GERALD | DP | Non-Final OA | — | Pending | Dec 29, 2023 | |
| 18575804 | Method of Administering Anti-HPA-1a Monoclonal Antibody | Rallybio Ipa, LLC | STOICA, ELLY GERALD | §102§103§112 | Non-Final OA | — | Pending | Dec 29, 2023 | |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | Queen Mary University Of London | FAUST, AMBER KATHLEEN | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 | |
| 18290252 | USE OF RAGE INHIBITORS TO TREAT CANCER-RELATED COGNITIVE DECLINE | Georgetown University | JARRELL, NOBLE E | 1699 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Georgetown University | BARSKY, JARED | 1628 | §103 | Final Rejection | 89d overdue | Pending | Apr 22, 2023 |
| 18041080 | CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS | Angiocrine Bioscience, Inc. | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2023 |
| 17924980 | METHOD OF TREATMENT OF CANCER OR TUMOUR | USWM CT,LLC | POPA, ILEANA | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Jan 23, 2023 |
| 18003124 | ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY | Angiocrine Bioscience, Inc. | SCHUBERG, LAURA J | 1631 | §103Other | Non-Final OA | 25d overdue | Pending | Dec 22, 2022 |
| 18011171 | Administration of CEBP-Beta Antagonist and Methods of Use | Sapience Therapeutics, Inc. | STEELE, AMBER D | 1658 | §103§112DP | Final Rejection | — | Pending | Dec 17, 2022 |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | Oxford Biomedica (Us) LLC | GONZALES, JOSEPHINE MARIA | 1631 | §102§103 | Non-Final OA | 69d | Pending | Dec 15, 2022 |
| 18009320 | CHIMERIC ANTIGEN RECEPTOR CELL | UCL Business Ltd | VIVLEMORE, TRACY ANN | 1638 | §103§112 | Non-Final OA | 86d overdue | Pending | Dec 08, 2022 |
| 17921606 | METHODS FOR ISOLATING AND CULTURING TUMOR CELLS | Georgetown University | TRAN, KHOA NHAT | 1632 | §103§112 | Final Rejection | — | Pending | Oct 26, 2022 |
| 17909427 | Replication Competent Virus Assay | Oxford Biomedica (Uk) Limited | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | 69d | Pending | Sep 05, 2022 |
| 17821884 | ADENO-ASSOCIATED VIRUS FORMULATIONS | Oxford Biomedica (Us) LLC | GILL, RACHEL B | 1671 | §103 | Final Rejection | 29d | Pending | Aug 24, 2022 |
| 17812304 | METHOD OF TREATMENT OF CANCER OR TUMOUR | USWM CT,LLC | LU, CHENG | 1642 | §103§112Other | Final Rejection | — | Pending | Jul 13, 2022 |
| 17775922 | Production System | Oxford Biomedica (Uk) Limited | PENNINGTON, KATIE LEIGH | 1634 | §103§112DP | Non-Final OA | 30d | Pending | May 11, 2022 |
| 17724493 | PLANT-BASED BABY FOOD COMPOSITIONS | Nunona Inc. | NGUYEN, THANH H | 1792 | §103 | Non-Final OA | 15d | Pending | Apr 20, 2022 |
| 17629378 | Enhancing Production of Lentiviral Vectors | Oxford Biomedica (Uk) Limited | BATES, KEENAN ALEXANDER | 1631 | §112DPOther | Non-Final OA | — | Pending | Jan 22, 2022 |
| 17503088 | Gene Therapy | Ospedale San Raffaele S.R.I. | CORDAS, EMILY ANN | 1632 | §103§112 | Non-Final OA | 69d | Pending | Oct 15, 2021 |
| 17196631 | METHODS AND COMPOSITIONS FOR DETECTION OF HPV DNA AND DIAGNOSIS AND MONITORING OF HPV-ASSOCIATED CANCERS | Memorial Sloan Kettering Cancer Center | HANEY, AMANDA MARIE | 1682 | §103 | Non-Final OA | 7d | Pending | Mar 09, 2021 |
| 17060993 | Magnetically Stabilized Total Hip Replacement Prosthesis | Fellowship Of Orthopaedic Researchers, Inc. | WOLF, MEGAN YARNALL | 3774 | §103 | Final Rejection | — | Pending | Oct 01, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial